What is the recommended management for a 63-year-old obese male with severe right hip osteoarthritis, inadequate pain control on acetaminophen, type 2 diabetes, hypertension, and current medications (epixiban, metoprolol succinate, metformin)?

Recommendation for Severe Hip Osteoarthritis Management

This patient should be referred for total hip arthroplasty (THA) evaluation after optimizing modifiable risk factors, specifically targeting BMI reduction and diabetes control, while transitioning pain management to NSAIDs or duloxetine in the interim. 1

Rationale for Surgical Referral

This 63-year-old presents with severe, end-stage hip osteoarthritis evidenced by:

• Severe joint space narrowing and osteophyte formation on radiographs
• Inadequate pain control despite acetaminophen 3000 mg daily
• Significant functional limitation (positive FABER test, limited external rotation)
• Classic examination findings (pain with internal/external rotation)

The 2023 AAOS guidelines explicitly demonstrate that patients with this clinical and radiographic presentation are appropriate THA candidates 1. The case examples show similar patients proceeding to THA after optimization.

Pre-Surgical Optimization Required

Before proceeding with THA, address these modifiable risk factors:

1. Weight Reduction (Priority)

• Current BMI of 34 kg/m² increases adverse events and reduces patient-reported outcomes after THA 1
• Target: Reduce BMI closer to 30 kg/m² or below if feasible
• Timeline: 3-4 months of structured weight loss program

2. Diabetes Optimization

• Ensure HbA1c < 7.5% (ideally < 7.0%) before surgery
• Poorly controlled diabetes increases postoperative adverse events 1
• Continue metformin - emerging evidence shows metformin may provide additional benefit for OA pain in obese patients with metabolic syndrome 2

3. Blood Pressure Management

• Current BP 134/84 is acceptable but monitor closely
• Continue metoprolol succinate - no contraindication for THA
• Continue epixaban - will require perioperative bridging protocol

Interim Pain Management Strategy

While optimizing for surgery (3-4 month period):

First-Line Options:

Option A: Intra-articular Corticosteroid Injection

• Strongly recommended for hip OA 3
• Must use ultrasound or fluoroscopic guidance for hip joints 3
• Provides short-term relief (weeks to months)
• Can be repeated if needed during optimization period

Option B: Oral NSAIDs

• Strongly recommended as first-line pharmacologic treatment 3, 4
• Caution: Patient is on epixaban (anticoagulant)
• NSAIDs increase GI bleeding risk when combined with anticoagulation
• If used, must use lowest effective dose with proton pump inhibitor
• Monitor blood pressure as NSAIDs can elevate BP in hypertensive patients 5, 6

Option C: Duloxetine 30-60 mg daily

• Conditionally recommended for hip OA 3
• Safer option given anticoagulation
• No bleeding risk or BP elevation
• Effective for centralized pain component

Acetaminophen Status:

• Discontinue or reduce acetaminophen - evidence shows minimal efficacy as monotherapy for OA, and patient has already failed at maximum dose (3000 mg/day) 3
• The ACR 2020 guidelines note acetaminophen has very small effect sizes and may be ineffective for most individuals 3

Avoid:

• Tramadol or opioids - consensus recommendation against use for hip OA 1, 3
• Intra-articular hyaluronic acid - strong recommendation AGAINST for hip OA 1, 3

Recommended Treatment Algorithm

Immediate (Week 1):

1. Refer to orthopedic surgery for THA evaluation
2. Initiate ultrasound-guided intra-articular corticosteroid injection for immediate pain relief
3. Start duloxetine 30 mg daily (titrate to 60 mg after 1 week if tolerated)
4. Reduce acetaminophen to PRN use only

Months 1-4 (Optimization Phase):

1. Structured weight loss program (dietitian referral, consider GLP-1 agonist if appropriate)
2. Check HbA1c - optimize to <7.5%
3. Physical therapy for hip-specific exercises and gait training
4. Repeat corticosteroid injection at 2-3 months if pain recurs
5. Continue duloxetine

Month 4-5:

1. Reassess surgical candidacy once BMI and HbA1c optimized
2. Proceed with THA if goals achieved

Critical Medication Considerations

Metoprolol Succinate:

• Continue without modification 7
• No contraindication for THA
• Perioperative beta-blocker continuation reduces cardiac events

Epixaban:

• Continue for now
• Will require perioperative management (typically hold 48-72 hours pre-op)
• Coordinate with orthopedic surgery and cardiology

Metformin:

• Continue and do not discontinue 2
• Recent 2025 RCT shows metformin reduces knee OA pain in obese patients (effect size 0.43, p=0.01)
• May provide additional benefit for hip OA given metabolic phenotype
• Safe to continue perioperatively (hold day of surgery only)

Common Pitfalls to Avoid

1. Delaying surgical referral - This patient has end-stage disease; conservative management alone is insufficient
2. Using hyaluronic acid injections - Strong evidence against efficacy in hip OA 1
3. Prescribing opioids - Consensus against use; patient must optimize off narcotics before THA 1
4. Combining NSAIDs with anticoagulation without GI protection - High bleeding risk
5. Proceeding to surgery without optimization - Increases complications significantly 1